Indication
Pemphigus vulgaris
Pemphigus vulgaris is a rare, severe, chronic autoimmune mucocutaneous disorder that primarily affects adults between 40 and 60 years of age. Read more about Pemphigus vulgaris
3 drugs 3 manufacturers
Drugs that treat it
Common Pemphigus vulgaris therapies.
RUXIENCE (rituximab-pvvr)
RIABNI (rituximab-arrx)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonPemphigus vulgaris is a rare, severe, chronic autoimmune mucocutaneous disorder that primarily affects adults between 40 and 60 years of age.
Pathophysiologically, it is characterized by pathogenic immunoglobulin G autoantibodies directed against desmoglein 3 and often desmoglein 1, which are critical cadherin proteins responsible for intercellular adhesion between keratinocytes.
This antibody-mediated disruption triggers intraepidermal acantholysis, resulting in widespread loss of cell-cell adhesion.
Clinically, the disease presents with extremely fragile, flaccid bullae and painful, non-healing erosions that typically initiate in the oral mucosa before progressing to involve the skin and other mucous membranes.
- nih.gov
Pemphigus vulgaris is a rare, severe, chronic autoimmune mucocutaneous disorder that primarily affects adults between 40 and 60 years of age Clinically, the disease presents with extremely fragile, flaccid bullae and painful, non-healing erosions that typically initiate in the oral mucosa before progressing to involve the skin and other mucous membranes
- nih.gov
Pemphigus vulgaris is a rare, severe, chronic autoimmune mucocutaneous disorder that primarily affects adults between 40 and 60 years of age Pathophysiologically, it is characterized by pathogenic immunoglobulin G autoantibodies directed against desmoglein 3 and often desmoglein 1, which are critical cadherin proteins responsible for intercellular adhesion between keratinocytes Clinically, the disease presents with extremely fragile, flaccid bullae and painful, non-healing erosions that typicall...
- nih.gov
This antibody-mediated disruption triggers intraepidermal acantholysis, resulting in widespread loss of cell-cell adhesion
- nih.gov
Clinically, the disease presents with extremely fragile, flaccid bullae and painful, non-healing erosions that typically initiate in the oral mucosa before progressing to involve the skin and other mucous membranes
- nih.gov
Clinically, the disease presents with extremely fragile, flaccid bullae and painful, non-healing erosions that typically initiate in the oral mucosa before progressing to involve the skin and other mucous membranes
Personalize your experience
Follow Pemphigus vulgaris and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.